TMPRSS7 inhibitors are a class of chemical compounds designed to specifically target the TMPRSS7 protein, a member of the transmembrane serine protease family involved in various cellular functions. These inhibitors work by binding to the active site of the TMPRSS7 protein, where they block the interaction between the enzyme and its natural substrates. By occupying the active site, TMPRSS7 inhibitors prevent the protein from catalyzing its usual biochemical reactions, effectively halting its proteolytic activity. In addition to directly blocking the active site, some TMPRSS7 inhibitors may bind to allosteric sites, inducing conformational changes that reduce the protein's overall functionality. The binding interactions between TMPRSS7 inhibitors and the protein are stabilized by non-covalent forces such as hydrogen bonds, hydrophobic interactions, van der Waals forces, and electrostatic interactions, which ensure the stability and effectiveness of the inhibitor-protein complex.
The structural diversity of TMPRSS7 inhibitors is essential to their ability to interact effectively with the protein. These inhibitors often feature functional groups like hydroxyl, carboxyl, or amine groups that facilitate hydrogen bonding and ionic interactions with key residues in the TMPRSS7 protein's active site. Aromatic rings and heterocyclic cores are also common in the design of TMPRSS7 inhibitors, as they contribute to hydrophobic interactions with non-polar regions of the protein, further stabilizing the inhibitor's binding. The physicochemical properties of TMPRSS7 inhibitors, such as molecular weight, lipophilicity, solubility, and polarity, are carefully optimized to ensure that the inhibitors can efficiently bind to the protein and remain stable in various biological environments. The balance of hydrophobic and hydrophilic regions within the inhibitor molecules is crucial for ensuring selective binding to both polar and non-polar regions of the TMPRSS7 protein, leading to robust and effective inhibition under a variety of conditions.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide may inhibit the transcription of TMPRSS7 by interfering with transcription factors related to serine protease gene expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin potentially reduces TMPRSS7 expression by inhibiting mTOR, a kinase that regulates protein synthesis and cell growth. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D binds to DNA and may halt TMPRSS7 transcription by preventing RNA polymerase from synthesizing mRNA. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin can inhibit RNA polymerase II and possibly decrease TMPRSS7 mRNA synthesis. | ||||||
Mitotane | 53-19-0 | sc-205754 sc-205754A | 100 mg 1 g | $72.00 $166.00 | 1 | |
Mitotane could reduce TMPRSS7 expression by disrupting mitochondrial function and inducing oxidative stress that affects protein synthesis. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide inhibits eukaryotic protein synthesis which may lead to a reduction in TMPRSS7 protein levels. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
5-Fluorouracil may indirectly lower TMPRSS7 expression by inhibiting thymidylate synthase, thereby reducing DNA and RNA synthesis. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib can induce proteasome inhibition, which might cause downregulation of TMPRSS7 through reduced protein turnover. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin inhibits topoisomerase I, which could result in decreased transcription and subsequent lower expression of TMPRSS7. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine interferes with lysosomal activity and autophagy, which might impact TMPRSS7 protein levels due to altered cellular protein degradation pathways. | ||||||